Age and disease severity predict choice of atypical neuroleptic: A signal detection approach to physicians' prescribing decisions

Journal of Psychiatric Research

Volumn 37, Issue 6, 2003, Pages 535-538

  Yesavage, Jerome A ^a,b   Hoblyn, Jennifer ^a,b   Sheikh, Javaid ^a,b   Tinklenberg, Jared R ^a,b   Noda, Art ^b   O'Hara, Ruth ^b   Fenn, Catherine ^b   Mumenthaler, Martin S ^b   Friedman, Leah ^b   Kraemer, Helena C ^b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age; Neuroleptics; Schizophrenia; Signal detection

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; RISPERIDONE;

AGE; ARTICLE; DATA BASE; DECISION MAKING; DISEASE SEVERITY; GENDER; HUMAN; MEDICAL RECORD; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; RACE; SCHIZOPHRENIA; SIGNAL DETECTION; STATISTICAL ANALYSIS;

EID: 10744221759     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(03)00053-0     Document Type: Article

References (11)

1. Brown C., Markowitz J., Moore T., Parker N. Atypical antipsychotics. Part II: Adverse effects, drug interactions, and costs. Annals of Pharmacotherapy. 33:1999;210-217.
2. Fleischhacker W.W. The pharmacology of schizophrenia. Current Opinion in Psychiatry. 12:1999;53-59.
3. Killen J.D., Fortmann S.P., Kraemer H.C., Varady A.N., Davis L., Newman B. Interactive effects of depression symptoms, nicotine dependence, and weight change on late smoking relapse. Journal of Consulting and Clinical Psychology. 64:1996;1060-1067.
4. Kraemer H.C. Evaluating medical tests: objective and quantitative guidelines. 1992;Sage Publications, Newbury Park, CA.
5. Leslie D.L., Rosenheck R.A. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system. Medical Care. 39:2001;923-933.
6. Leslie D.L., Rosenheck R.A. The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia. Journal of Nervous and Mental Disorders. 189:2001;377-383.
7. Markowitz J., Brown C., Moore T. Atypical antipsychotics. Part 1: Pharmacology, pharmacokinetics, and efficacy. Annals of Pharmacotherapy. 33:1999;73-85.
8. O'Hara R., Thompson J.M., Kraemer H.C., Fenn C., Taylor J.L., Ross L.et al. Which Alzheimer patients are at risk for rapid cognitive decline? Journal of Geriatric Psychiatry and Neurology. 15:2002;233-238.
9. Rice D.P. The economic impact of schizophrenia. Journal of Clinical Psychiatry. 60:1999;4-6.
10. Winkleby M.A., Flora J.A., Kraemer H.C. A community-based heart disease intervention. predictors of change American Journal of Public Health. 84:1994;767-772.
11. Wyatt R.J., Henter I., Leary M.C., Taylor E. An economic evaluation of schizophrenia: 1991. Social Psychiatry and Psychiatric Epidemiology. 30:1995;196-205.